Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 617: Safety and PK of CAP256J3LS in Healthy Adults
NCT06585891Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of VRC-HIVMAB0121-00-AB in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and tolerability of CAP256J3LS at 24 weeks. Started Oct 2024; status: completed.
02
Drugs
VRC-HIVMAB0121-00-AB
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06585891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585891.